The CCTC is divided into a series of research specific groups. Most are disease site related, e.g. breast, lung, but several are related to treatment or trial type e.g. radiotherapy or early phase.

Cambridge Cancer Centre holds excellent information about the various types of trials (see link at the bottom of page) .

Current CCTC trials include:

  • CamBMT1 - Cambridge Brain Mets Trial 1: A proof-of-principle phase 1b/ randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.
  • ​CAM-PLEX - To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor, at potentially active plasma concentrations and assess its impact on the immune microenvironment in patients with advanced pancreatic, high grade serous ovarian and colorectal adenocarcinomas.
  • CANCAP02 - A study into the pharmacodynamic biomarker effects of AZD2014 (an mTOR1/2 inhibitor) given prior to radical prostatectomy.
  • CANCAP03 - A study into the pharmacodynamic biomarker effects of Olaparib (a PARP Inhibitor) ± Degarelix (a GnRH antagonist) given prior to radical prostatectomy.
  • GALA-BIDD - Improving the intra-operative diagnosis of high-grade glioma using a fluorescence biomarker.
  • P3BEP: A randomised phase III trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours.
  • PARTNER - A randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of Olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA.
  • ​Persephone - Duration of Trastuzumab with Chemotherapy in Patients with Early Breast Cancer: Six Months versus Twelve.
  • PRICKLE - Pancreatic Resectability in Cancers with Known Limited Extension (PRICKLE) - A single-centre phase 2a study of gemcitabine plus nab-paclitaxel for borderline unresectable locally advanced pancreatic cancer.
  • SIEGE - Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic ductal adenocarcinoma.
  • VoxTox - Linking radiation dose at the voxel level with toxicity.

More information about these trials (and others) can be found on the CRUK Cambridge Centre website.


Show on hub page: